SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fenaux P, Chomienne C, Degos L. Acute promyelocytic leukemia: biology and treatment. Semin Oncol 1997;24:92102.
  • 2
    Tallman MS. Differentiating therapy in acute myeloid leukemia. Leukemia 1996;10:12621268.
  • 3
    Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol 1990;8:19131921.
  • 4
    Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med 1992;117:292296.
  • 5
    Warrell RP Jr, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993;329:177187.
  • 6
    Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Grignani F, Pelicci PG. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994;83:1025.
  • 7
    Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002;99:759767.
  • 8
    Lo Coco F, Nervi C, Avvisati G, Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia 1998;12:18661880.
  • 9
    Sutherland DR, Keating A. The CD34 antigen: structure, biology, and potential clinical applications. J Hematother 1992;1:115129.
  • 10
    Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood 1996;87:113.
  • 11
    Foley R, Soamboonsrup P, Carter RF, Benger A, Meyer R, Walker I, Wan Y, Patterson W, Orzel A, Sunisloe L, Leber B, Neame PB. CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform. Am J Hematol 2001;67:3441.
  • 12
    Kanda Y, Hamaki T, Yamamoto R, Chizuka A, Suguro M, Matsuyama T, Takezako N, Miwa A, Kami M, Hirai H, Togawa A. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer 2000;88:25292533.
  • 13
    Porwit-MacDonald A, Janossy G, Ivory K, Swirsky D, Peters R, Wheatley K, Walker H, Turker A, Goldstone AH, Burnett A. Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 over-expression in acute myelogenous leukemia M2 with t(8;21). Blood 1996;87:11621169.
  • 14
    Pallisgaard N, Hokland P, Riishoj DC, Pedersen B, Jorgensen P. Multiplex reverse transcription–polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998;92:574588.
  • 15
    Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Wood WG. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813819.
  • 16
    Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:10511062.
  • 17
    Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T, Diaz-Mediavilla J, Fioritoni G, Gonzalez JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:12471253.
  • 18
    Chou WC, Tang JL, Yao M, Liang YJ, Lee FY, Lin MT, Wang CH, Shen MC, Chen YC, Tien HF. Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans-retinoic acid treatment. Leukemia 1997;11:921928.
  • 19
    Bolognesi E, Cimino G, Diverio D, Rapanotti MC, D'Alfonso S, Fleischhauer K, Migliaretti G, Momigliano-Richiardi P. HLA class I in acute promyelocytic leukemia (APL): possible correlation with clinical outcome. Leukemia 2000;14:393398.
  • 20
    Murray CK, Estey E, Paietta E, Howard RS, Edenfield WJ, Pierce S, Mann KP, Bolan C, Byrd JC. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol 1999;17:293297.
  • 21
    Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, Boccuni P, Di Noto R, Pane F, Annunziata M, Schiavone EM, De Simone M, Guglielmi C, Del Vecchio L, Lo Coco F. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 2000;18:12951300.
  • 22
    Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA, Warrell RP Jr. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-α isoform, and CD13 expression in patients treated with all-trans-retinoic acid. Blood 1994;84:38433849.
  • 23
    Albitar M, Chang KS, Pierce S, Kantarjian H, Estey E. The short form of PML-RARα fusion transcript is associated with poor survival. Leuk Res 1999;23:8992.
  • 24
    Slack JL, Willman CL, Andersen JW, Li YP, Viswanatha DS, Bloomfield CD, Tallman MS, Gallagher RE. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARα isoform: results from intergroup protocol 0129. Blood 2000;95:398403.
  • 25
    Gonzalez M, Barragan E, Bolufer P, Chillon C, Colomer D, Borstein R, Calasanz MJ, Gomez-Casares MT, Villegas A, Marugan I, Roman J, Martin G, Rayon C, Deben G, Tormo M, Diaz-Mediavilla J, Esteve J, Gonzalez-San Miguel J, Rivas C, Perez-Equiza K, Garcia-Sanz R, Capote FJ, Ribera JM, Arias J, Leon A, Sanz MA. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: a study of the PETHEMA group. Br J Haematol 2001;114:99103.
  • 26
    Fukutani H, Naoe T, Ohno R, Yoshida H, Miyawaki S, Shimazaki C, Miyake T, Nakayama Y, Kobayashi H, Goto S, Takeshita A, Kobayashi S, Kato Y, Shiraishi K, Sasada M, Ohtake S, Murakami H, Kobayashi M, Endo N, Shindo H, Matsushita K, Hasegawa S, Tsuji K, Ueda Y, Tominaga N, Furuya H, Inoue Y, Takeuchi J, Morishita H, Lida H. Isoforms of PML–retinoic acid receptor α fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans-retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1995;9:14781482.
  • 27
    Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH. Association of PML-RARα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997;90:16561663.
  • 28
    Guglielmi C, Martelli MP, Diverio D, Fenu S, Vegna ML, Cantu-Rajnoldi A, Biondi A, Cocito MG, Del Vecchio L, Tabilio A, Avvisati G, Basso G, Lo Coco F. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol 1998;102:10351041.
  • 29
    Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, Ohno R. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans-retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998;16:7885.